

1 **Association between Cardiovascular Disease Risk and long COVID-19: A**
2 **Systematic Review and Meta-analysis**

3 Yunxia Huang^{a, b}, Zhuofeng Wen^{a, b}, Hongbin Luo^{a, b}, Yijie Liao^{a, b}, Zisheng Chen^{a, *}

4 ^aDepartment of Respiratory and Critical Care Medicine, the Sixth Affiliated Hospital
5 of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan 511518,
6 China;

7 ^bThe Sixth Clinical Medical School of Guangzhou Medical University;

8 * Corresponding author: E-mail addresses: williamstdb@gzhmu.edu.cn.

9

10 **ABSTRACT**

11 **Objectivate** To assess demographic characteristics and investigate the correlation
12 between cardiovascular diseases and long COVID-19 patients.

13

14 **Methods** Comprehensive details, encompassing the first author's name, publication
15 year, sample inclusion criteria, sample size, and demographic characteristics,
16 including age and gender of participants, were systematically extracted from all
17 incorporated studies. Meanwhile, the analysis encompassed the assessment of the risk
18 associated with nineteen cardiovascular outcomes.

19

20

21 **Results** A total of 3, 201 potentially eligible studies were initially identified for
22 consideration. Following rigorous literature screening and quality control measures,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 eighteen studies, encompassing 46, 083, 975 patients, met the specified criteria. In
24 comparison to the control cohort, our investigation unveiled a heightened risk of 19
25 cardiovascular outcomes associated with long COVID-19. Our meta-analysis revealed
26 a pooled OR of 1.68 (95% CI 1.55-1.81) ($I^2 = 69.1\%$, $p = 0.000$) for the overall risk of
27 cardiovascular outcomes, indicating an elevated risk of cardiovascular diseases in
28 individuals affected by long COVID-19. While the heterogeneity was relatively high,
29 it is essential to acknowledge that all studies inherently carry an unavoidable risk of
30 bias, irrespective of their quality rating. Moreover, there appears to be no significant
31 publication bias based on the funnel plot, Begg's, and Egger's tests. Sensitivity
32 analysis did not reveal substantial alterations in the overall stability of the results.

33

34 **Conclusions** Our meta-analysis substantiates that individuals afflicted with long
35 COVID-19 face an elevated risk of developing cardiovascular diseases. Routine
36 assessment of cardiac function is deemed essential for a long COVID-19 high-risk
37 cardiovascular disease population. Timely interventions have the potential to mitigate
38 the risk of cardiovascular diseases and associated mortality in this population.

39

40 **TRIAL REGISTRATION PROSPERO Identifier:** CRD42023455701

41

42 **Keywords:** Coronavirus disease 2019; Cardiovascular Disease; Long COVID-19.

43

44 **Abbreviations:** WHO, World Health Organization; HR, Hazard ratio; RR, risk ratio;

45 OR, odds ratio; CI, confidence interval; REM, random-effects model; ACE2,
46 angiotensin-converting enzyme 2; SARS-CoV-2, Severe Acute Respiratory
47 Syndrome Coronavirus 2 CoV; MESH, Medical Subject Headings; NOS,
48 Newcastle-Ottawa Scale; FEM, fixed-effect model; BMI, Body Mass Index; IL,
49 interleukin;

50

51 **1. Introduction**

52 Since the COVID-19 global pandemic, there have been over 771, 151, 224 cumulative
53 cases and 6, 960, 783 deaths of COVID-19 all over the world, as of 4 October 2023¹.

54 Recently, more and more researches have posited that COVID-19 may exert
55 deleterious effects on patients beyond the acute phase, including potential negative
56 impacts on respiratory, neurologic, mental, gastrointestinal, and cardiovascular
57 health²⁻⁵. Consequently, the terminology 'long COVID' or 'post-COVID-19 syndrome'
58 has emerged, specifically denoting the persistent clinical manifestations observed
59 beyond the acute phase⁶. This fluctuating condition can be classified into two stages,
60 namely post-acute and chronic, delineated by the duration of follow-up during which
61 the symptoms manifest⁷. In the view of some studies, approximately one-eighth of the
62 global population is projected to experience post-COVID-19 conditions. This implies
63 that, considering over 651 million documented COVID-19 cases worldwide and a
64 conservative estimate of a 10% incidence rate among infected individuals, around 65
65 million individuals worldwide may be affected by long COVID^{8,9}. During the
66 trajectory of long COVID-19, prevalent symptoms and signs include olfactory

67 dysfunction, dyspnea, gustatory dysfunction, cough, fatigue, myalgia, among others,
68 contributing to a diminished quality of life and decreased work efficiency¹⁰. Moreover,
69 COVID-19 is implicated in significant multiorgan dysfunction, encompassing
70 myocardial injury, acute respiratory distress syndrome, systemic shock, liver injury,
71 renal injury, etc^{11,12}.

72

73 Relevant studies suggest that the zinc metallopeptidase angiotensin-converting
74 enzyme 2 (ACE2), responsible for converting angiotensin II to angiotensin, serves as
75 the functional receptor for Severe Acute Respiratory Syndrome Coronavirus 2 CoV
76 (SARS-CoV-2), whose interaction is implicated in myocardial damage, representing
77 one potential mechanism, but the specific mechanisms remain elusive^{13,14}. As matters
78 stand, there is an increasing number of reports highlighting cardiovascular
79 complications in long COVID, including arrhythmia, inflammatory heart disease,
80 heart failure and various other cardiac disorders^{15,16}. Actually, we have to
81 acknowledge the existing controversy still surrounding the relationship between
82 cardiovascular disease and long COVID-19. Specifically, regarding ischemic heart
83 disease, findings from Hannah R Whittaker et al² suggest a lower risk for long
84 COVID-19 patients, while studies by Kwan Hong et al¹⁷ and Yan Xie et al¹⁸ present
85 contrasting perspectives. Consequently, our current understanding of the association
86 between cardiovascular disease and long COVID-19 remains limited. Further
87 comprehensive evidence is imperative to establish a definitive association between
88 cardiovascular disease and patients with long COVID-19.

89

90 As a consequence, we analyzed and reviewed relevant cohort studies to sort out the
91 association of long COVID-19 patients with cardiovascular disease risk by the mean
92 of meta-analysis comprehensively and deeply.

93

94 **2. Materials and methods**

95 **2. 1. Literature search**

96 We performed a comprehensive meta-analysis of prospective and retrospective cohort
97 studies documenting at least one combination of risk factors and outcomes. Our
98 search strategy encompassed multiple databases, such as Web of Science, Scopus,
99 Cochrane Library, Embase and PubMed, up to August 18, 2023, and was limited to
100 articles published solely in English. Our search used the keywords "long COVID-19",
101 "cardiovascular disease" and their Medical Subject Headings (MeSH) terms. Studies
102 were required to fulfill the following medical standards: (1) only include
103 prospective/retrospective cohort studies and case-control studies; (2) Patients with
104 long COVID-19 were studied; (3) Outcome indicators: the risk of cardiovascular
105 disease among patients with confirmed long COVID-19 (HR, RR and OR, with 95%
106 CI); (4) Written in English only. Studies were excluded if they lacked the provision of
107 OR/RR/HR with 95% CI, exhibited poor methodological quality, reported individual
108 cases, or lacked the specified indicators of accomplishment mentioned above. Our
109 research was registered in the Prospective Register of Systematic Reviews
110 (PROSPERO ID CRD42023455701).

111

112 **2. 2. Data acquisition**

113 Four investigators (Y. H. , Z. W. , H. L. , Y. L.) independently extracted data and
114 resolved discrepancies through consensus by four reviewers. The results underwent
115 review by the senior investigator (Z. C.). When available, information on target
116 outcomes was documented using WPS software. General details, including the first
117 author's name, publication year, sample inclusion criteria, sample size, and
118 demographic data such as age and gender of study participants, were systematically
119 collected from all included studies. Incidence outcomes were compared between the
120 COVID-19 and non-COVID-19 groups.

121

122 **2. 3. Quality assessment**

123 The risk of bias in the included cohort studies was evaluated using the
124 Newcastle-Ottawa Scale (NOS). Studies achieving a score of at least 7 out of 10 were
125 classified as high-quality studies.

126

127 **2. 4. Statistical analyses in Meta-analysis**

128 We conducted meta-analyses using a statistical software package (Stata 11.0).
129 Heterogeneity among the studies was assessed through χ^2 analysis. If the
130 inconsistency values (I^2) exceeded 50%, a REM was applied; otherwise, a fixed-effect
131 model (FEM) was utilized. In the presence of heterogeneity, we explored its source
132 through subgroup analysis and sensitivity analysis. The combined HR, RR, OR, with

133 its corresponding 95% CI was computed. Subsequently, funnel plots, Begg and Egger
134 bias index tests, and meta-regression were employed to identify potential publication
135 bias. All P values were two-sided, and statistical significance was set at $P < 0.05$.

136

137 **3. Results**

138 **3.1. Search results and study characteristics**

139 The selection process is depicted in Figure. 1 via a flowchart. 3, 201 studies were
140 deemed potentially eligible across various databases. 591 duplicates were excluded,
141 then 2610 left. After extensively comparing the studies' relevant information, 1, 001
142 researchers were included, but 1,609 were excluded (150 case reports, 371 conference
143 abstracts, 197 comments, 20 editorials, 71 letters, 117 notes, 631 review, 52
144 meta-analyses). According to the studies for the title and abstract screening, 136
145 articles were taken into the next round, and 865 were dismissed (60 not related to
146 COVID-19, 270 irrelevant research, 513 about other diseases, 22 not cohort studies).
147 Finally, eighteen articles remained after reading the full articles, and 118 were ruled
148 out (17 studies with incomplete outcomes, 88 irrelevant researches, 13 irrelevant
149 interventions).

150

151 The characteristics of the included studies are presented in Table. 1 Eighteen cohort
152 studies, including 3 prospective cohort studies and 15 retrospective cohort studies,
153 were conducted in developed and developing countries involving different races. The
154 total number of patients included in these studies was 46, 083, 975 of which more

155 than 37, 475, 604 were in the no COVID-19 group, and over 8, 327, 779 were in the
156 COVID-19 group. The duration of the studies ranged from 5 to 39 months. The male
157 ranged from 41.2% to 90.42%, and the mean age of the participants ranged from
158 27.99 (± 7.96) to 73.85 (± 4.50) years. Only seven studies reported the mean Body
159 Mass Index (BMI) of the no COVID-19 group, which ranged from 26 (± 5.0) kg/m^2 to
160 30.2 (± 5.7) kg/m^2 , while the mean BMI of the COVID-19 group ranged from 27.1
161 (± 6.7) kg/m^2 to 31.00 (± 6.06) kg/m^2 . Furthermore, there were eight studies collected
162 the smoking history of the individuals: 5.52% to 57.43% in no COVID-19 group
163 while 4.41% to 59.69% in COVID-19 group. In addition, eleven researches provided
164 the prevalence of diabetes: 7.42% to 77.22% in no COVID-19 group while 8.34% to
165 75.61% in COVID-19 group. What's more, there were also five studies recorded the
166 prevalence of high cholesterol: 8.63% to 74.29% in no COVID-19 group while 8.80%
167 to 72.79% in COVID-19 group. Lastly, three articles mentioned the morbidity of
168 coronary heart disease: 22.12% to 78.21% in no COVID-19 group, then, 22.12% to
169 35.74% in COVID-19 group.

170

171 **3. 2. Quality assessment**

172 We used the NOS, a measure of bias, to analyze the case-control and cohort studies.
173 Only studies at least with a minimum score of 7 were deemed to be of high quality. In
174 our meta-analysis, fifteen articles had a performance score of more than $7^{2-4,16-27}$, and
175 three studies scored 6 as medium quality²⁸⁻³⁰, as shown in Table. 2.

176

177 **3. 3. 1 Cardiovascular disease risk in long COVID-19 patients**

178 Compared to the control cohort, our meta-analysis showed a pooled OR of 1.87 (95%
179 CI 1.56-2.25) ($I^2 = 99.4\%$, $p= 0.000$) for the overall risk of cardiovascular events,
180 while major cardiovascular diseases (HR 1.52; 95% CI, 1.42-1.63; $I^2 = 69.1\%$, $P=$
181 0.021) and cardiovascular mortality (HR 1.65; 95% CI, 1.12-2.43; $I^2 = 39.7\%$, $P=$
182 0.173), indicating a higher risk among long COVID-19 patients (Supplementary
183 material online, Appendix Figure. 1 A-C)

184

185 We noted a significant positive association between long COVID-19 and 17
186 cardiovascular disease outcomes, consisting of acute coronary disease (RR 1.44; 95%
187 CI, 1.21-1.70; $I^2 = 87.8\%$, $P= 0.000$) (Supplementary material online, Appendix
188 Figure. 2), angina (RR 1.33; 95% CI, 1.17-1.52; $I^2 = 80.4\%$, $P= 0.000$)
189 (Supplementary material online, Appendix Figure. 3A), arrhythmia (RR 1.99; 95%
190 CI, 1.44-2.74; $I^2 = 98.3\%$, $P= 0.000$) (Supplementary material online, Appendix
191 Figure. 4A), atrial fibrillation (OR 1.48; 95% CI, 1.25-1.75; $I^2 = 93.3\%$, $P= 0.000$)
192 (Supplementary material online, Appendix Figure. 5A), atrial flutter (RR 1.31; 95%
193 CI, 0.97-1.76; $I^2 = 92.2\%$, $P= 0.000$) (Supplementary material online, Appendix
194 Figure. 6), bradycardia (OR 1.48; 95% CI, 1.34-1.64; $I^2 = 88.2\%$, $P= 0.000$)
195 (Supplementary material online, Appendix Figure. 7), cardiac arrest (RR 1.95; 95%
196 CI, 1.48-2.58; $I^2 = 63.4\%$, $P= 0.018$) (Supplementary material online, Appendix
197 Figure. 8), cardiogenic shock (RR 1.85; 95% CI, 1.59-2.14; $I^2 = 0.0\%$, $P= 0.604$)
198 (Supplementary material online, Appendix Figure. 9), cardiomyopathy (RR 1.52; 95%

199 CI, 1.25-1.83; $I^2 = 93.4\%$, $P= 0.000$) (Supplementary material online, Appendix
200 Figure. 10A), coronary disease(HR 1.65; 95% CI, 1.28-2.14; $I^2 = 81.7\%$, $P= 0.004$)
201 (Supplementary material online, Appendix Figure. 11), heart failure (OR 1.77; 95%
202 CI, 1.52-2.05; $I^2 = 96.4\%$, $P= 0.000$) (Supplementary material online, Appendix
203 Figure. 12A), hypertension (HR 2.39; 95% CI, 0.60-9.62; $I^2 = 99.6\%$, $P= 0.000$)
204 (Supplementary material online, Appendix Figure. 13), ischemic heart disease (HR
205 1.49; 95% CI, 1.13-1.96; $I^2 = 97.3\%$, $P= 0.000$) (Supplementary material online,
206 Appendix Figure. 14), myocardial infarction (OR 1.63; 95% CI, 1.42-1.86; $I^2 = 80.9\%$,
207 $P= 0.000$) (Supplementary material online, Appendix Figure. 15), myocarditis (OR
208 4.42; 95% CI, 2.94-6.67; $I^2 = 69.7\%$, $P= 0.000$) (Supplementary material online,
209 Appendix Figure. 16), pericarditis (OR 2.07; 95% CI, 1.59-2.69; $I^2 = 85.9\%$, $P= 0.000$)
210 (Supplementary material online, Appendix Figure. 17) and tachycardia (OR 1.76; 95%
211 CI, 1.63-1.90; $I^2 = 82.8\%$, $P= 0.000$) (Supplementary material online, Appendix
212 Figure. 18).

213

214 Long COVID-19 patients had a higher risk of developing cardiovascular disease risk
215 in relevant studies generally, according to the combined multivariate RR of 19
216 outcomes. A forest plot of the OR is shown in Figure. 2. We noted a significant
217 positive association between long COVID-19 and 19 cardiovascular disease outcomes
218 (RR 1.68; 95% CI, 1.55-1.81; $I^2 = 69.1\%$, $P= 0.000$).

219

220 The combined univariable OR of 4 outcomes was as well carried out, heart failure

221 (OR 1.56; 95% CI, 0.66-3.73; $I^2 = 97.6\%$, $P= 0.000$), myocarditis (OR 2.72; 95% CI,
222 0.40-18.32; $I^2 = 95.1\%$, $P= 0.000$), myocardial infarction (OR 2.37; 95% CI,
223 0.74-7.61; $I^2 = 77.5\%$, $P= 0.035$), pericarditis (OR 1.47; 95% CI, 0.29-7.42; $I^2 = 94.$
224 9% , $P= 0.000$), suggesting that confounding factors are prevalent, potentially
225 compromising the reliability of the results in univariate analysis, as shown in Figure.
226 3. However, the significance of aggregated analysis persists (OR 1.97; 95% CI,
227 1.11-3.52; $I^2 = 95.5\%$, $P= 0.000$).

228

229 3.3.2 Subgroup Analysis

230 A subgroup analysis was performed according to type of inpatient and outpatient, for
231 inpatient: angina (RR 1.70; 95% CI, 0.97-2.99; $I^2 = 87.9\%$, $P= 0.004$) and heart
232 failure (RR 1.47; 95% CI, 1.21-1.79; $I^2 = 86.0\%$, $P= 0.000$), as shown in
233 Supplementary material online, Appendix Figure. 3B and 12B, respectively; for
234 outpatient atrial fibrillation and flutter (RR 1.11; 95% CI, 0.82-1.52; $I^2 = 87.4\%$, $P=$
235 0.005) and heart failure (RR 1.06; 95% CI, 0.95-1.17; $I^2 = 0.0\%$, $P= 0.879$), as shown
236 in Supplementary material online, Appendix Figure. 5B and 12B, respectively.
237 Judging from the outcomes, it showed that the risk of HF significantly increased in
238 the inpatient group, may reflect severe COVID-19 would increase the risk of
239 long-term HF to some extent. Furthermore, there were 2 main subgroups for the
240 pathological type of cardiomyopathy, the subgroup analysis of ischemic
241 cardiomyopathy (RR 1.58; 95% CI, 1.11-2.26; $I^2 = 92.7\%$, $P= 0.000$) and
242 non-ischemic cardiomyopathy (RR 1.34; 95% CI, 1.10-1.64; $I^2 = 78.8\%$, $P= 0.000$),

243 as shown in Supplementary material online, Appendix Figure. 10B.

244

245 Meanwhile, there were also two other subgroup analyses, comprising ventricular
246 arrhythmias (RR 1.70; 95% CI, 1.36-2.13; $I^2 = 84.9\%$, $P= 0.000$) and atrial fibrillation
247 and flutter (RR 1.78; 95% CI, 0.97-3.25; $I^2 = 98.5\%$, $P= 0.000$), as shown in
248 Supplementary material online, Appendix Figure. 4B and 5C.

249

250 Considering the limitation of retrospective cohort study, we also conducted the risk of
251 cardiovascular outcomes only based on prospective cohort studies, which is more
252 reliable. It displayed that atrial fibrillation (HR 1.60; 95% CI, 0.87-2.95; $I^2 = 94.6\%$,
253 $P= 0.000$), heart failure (HR 1.74; 95% CI, 1.25-2.41; $I^2 = 65.9\%$, $P= 0.053$),
254 pericarditis (HR 4.47; 95% CI, 3.15-6.35; $I^2 = 0.0\%$, $P= 0.996$), as shown in
255 Supplementary material online, Appendix Figure. 19. Also Pooled analysis
256 demonstrates the significance of the aforementioned three outcomes (HR 2.14; 95%
257 CI, 1.52-3.01; $I^2 = 89.6\%$, $P= 0.000$).

258

259 **3. 4. Heterogeneity and publication bias**

260 The heterogeneity was relatively high, but with the help of Meta-regression, we
261 figured out that country, study design, total number of samples, age at baseline and
262 total months of follow-up should be responsible for
263 sources of heterogeneity to a certain extent Supplementary material online, Appendix
264 Figure. 20-39). Meanwhile, owing to the observational research's character, all studies

265 inherently entail an inevitable risk of bias, irrespective of their quality rating³¹. The
266 results of the funnel plot, Begg's, and Egger's tests collectively indicated the absence
267 of publication bias in the meta-analysis basically (Supplementary material online,
268 Appendix Figure. 40, Supplementary material online, Appendix Table. 2-19).

269

270 **3. 5. Sensitivity analysis**

271 Regarding the results displayed above, there was no discernible alteration in the
272 stability of the meta-analysis (Supplementary material online, Appendix Figure. 41).

273

274 **4. Discussion**

275 At present, a definitive mechanism explaining the pathophysiology of long-COVID
276 contributing to cardiovascular diseases remains not conclusive. One hypothesis
277 proposes that myocardial injury in COVID-19 may arise from either direct viral
278 invasion of cardiomyocytes or the presence of circulating inflammatory mediators,
279 including cytokines and/or endotoxins, or potentially a combination of both factors³².

280 Upon infection, there was an observed upregulation of ACE2, the receptor for
281 SARS-CoV-2, in the pulmonary alveolar epithelial barrier, vascular endothelial cells,
282 and cardiomyocytes³³. In single-nuclei RNA sequencing studies, robust expression of
283 ACE2 in the heart is evident in pericytes, vascular smooth muscle cells, fibroblasts,
284 and cardiomyocytes³⁴. An alternative hypothesis suggests that both hypo- and
285 hyper-immune responses may play a role in the severity of COVID-19, potentially
286 leading to systemic inflammatory responses or a cytokine storm, culminating in cell

287 death and multi-organ dysfunction³⁵. According to cell and animal models of
288 SARS-CoV-2 infection, coupled with transcriptional and serum profiling of
289 individuals with COVID-19, one experiment revealed a consistent and distinctive
290 inflammatory reaction, whose response was characterized by reduced levels of type I
291 and III interferons concomitant with elevated chemokine levels and prominent
292 expression of Interleukin- 6 (IL-6)³⁶.

293

294 Numerous cohort studies have identified an association between long-term
295 COVID-19 and diverse cardiovascular outcomes. However, a comprehensive
296 systematic meta-analysis assessing composite cardiac outcomes is currently lacking.
297 This study employed meta-analysis techniques to evaluate the relationship between
298 long COVID-19 and cardiovascular outcomes. Our meta-analysis, based on the
299 scrutiny of 18 articles comprising both retrospective and prospective studies,
300 encompassing 46, 083, 975 participants, revealed that individuals with long
301 COVID-19 face an increased risk of developing cardiovascular diseases overall.
302 Although the relatively high heterogeneity is acknowledged, it is inevitable for the
303 diversity arising from variations in countries, study designs, total sample sizes,
304 baseline ages, and durations of follow-up, as revealed by the results of
305 meta-regression. Additionally, the complexity of confounding factors presents a
306 challenge in achieving complete standardization. All included studies, even those with
307 a high rating, inherently entail an unavoidable risk of bias, owing to their
308 observational characteristic³¹. And we also hope to collect the data of long Covid

309 patients' BMI³⁷, smoking status³⁸⁻⁴⁰, diabetes⁴¹, high cholesterol^{42,43}, vaccination⁴⁴⁻⁴⁶
310 etc as much as possible, further identifying sources of heterogeneity. But in our study,
311 all the HRs, RRs and ORs are all over >1.0, as well as the absence of publication bias
312 based on the results of the funnel plot, Begg's, and Egger's tests, suggesting the model
313 is robust and reliable.

314

315 Hence, we propose that routine assessment of cardiac function is imperative for the
316 population with long COVID-19 who are at a heightened risk of cardiovascular
317 disease. Timely interventions have the potential to mitigate the risk of cardiovascular
318 diseases and associated mortality. At present, the management of long COVID and
319 CV sequelae encompass a range of therapeutic interventions⁵: these interventions
320 comprise various rehabilitation programs, both through telemedicine and in-person
321 consultations, targeting the amelioration of symptoms such as fatigue, cognitive
322 decline, and breathlessness; additionally, immunomodulatory treatments, including
323 steroids, laranilubmab, tocilizumab, atorvastatin, and colchicine, are also under
324 scrutiny; meanwhile, antifibrotic agents, like pirfenidone and LYT-100, as well as
325 anticoagulation strategies employing apixaban, are being experimented; furthermore,
326 there are therapies directed towards cognition enhancement, such as transcranial
327 stimulation, as well as metabolic modulators like niagen. What's more, Paxlovid
328 demonstrates higher efficacy in those harboring preexisting neurological or
329 cardiovascular conditions, individuals with immunosuppression and older patients⁴⁷.
330 But, the preeminent strategy for averting severe complications stemming from

331 SARS-CoV-2 infection is still vaccination^{48,49}. Furthermore, vigilant monitoring of
332 viral infection-associated cardiac injury remains imperative throughout the
333 management of COVID-19.

334

335 **5. Limitations**

336 We acknowledge certain limitations in our study that warrant consideration. Firstly,
337 several of our conducted meta-analyses displayed notable statistical heterogeneity,
338 which may potentially lead to an overestimation of the strength of associations, as
339 suggested by large meta-epidemiologic studies. The observed heterogeneity may be
340 attributed to adjusted confounding factors and other variables within the included
341 studies. Additionally, among the 18 articles analyzed, special attention should be
342 given to the cumulative duration of follow-up, given the chronic nature of
343 SARS-CoV-2 infection. Furthermore, retrospective cohort studies inherently introduce
344 a risk of bias. Therefore, there is an ongoing need for additional relevant cohort
345 studies, particularly prospective cohort studies, to enable a more comprehensive
346 analysis. But it is crucial to emphasize that all studies included in our analysis
347 provided risk factors through multivariable regression, ensuring the derivation of
348 robust conclusions.

349

350 **6. Conclusions**

351 In summary, our study furnishes evidence indicating that individuals long COVID-19
352 face a markedly elevated risk of developing cardiovascular outcomes. Implementing

353 intensified vaccination strategies, particularly with the latest COVID-19 vaccine, in
354 populations at a severe risk, and regularly monitoring cardiac function in those at a
355 high cardiovascular risk, may prove beneficial in mitigating the risk of cardiovascular
356 diseases and associated mortality in individuals with long COVID-19.

357

358 **Author Contributions**

359 Study design: ZC, YH; Data collection: YH, ZW, HL, YL; Data analyses: YH, ZC;
360 Results visualization: YH; Results interpretations: YH, ZC; Manuscript writing: YH,
361 ZC; Manuscript revising: YH, ZW, HL, YL ZC. All authors approved the final version
362 of the manuscript.

363

364 **Funding**

365 Special fund project for clinical research of Qingyuan People's Hospital
366 (QYRYCRC2023006), plan on enhancing scientific research in GMU
367 (GZMU-SH-301).

368

369 **Data Availability:**

370 The research contributions presented in this article are detailed in the
371 article/supplementary material; you can contact the relevant author for further
372 information.

373

374 **Declarations**

375 Competing interests The authors declare that they have no competing interests.

376

377 Reference

- 378 1. World Health Organization. Weekly operational update on COVID-19—4 July 2021. Weekly
379 operational update on COVID-19 - 4 October 2023 (who.int)
- 380 2. Whittaker HR, Gulea C, Koteci A, Kallis C, Morgan AD, Iwundu C, Weeks M, Gupta R, Quint JK.
381 GP consultation rates for sequelae after acute covid-19 in patients managed in the
382 community or hospital in the UK: population based study. *BMJ*. 2021;375:e065834. doi:
383 10.1136/bmj-2021-065834
- 384 3. Wan EYF, Mathur S, Zhang R, Yan VKC, Lai FTT, Chui CSL, Li X, Wong CKH, Chan EWY, Yiu KH, et
385 al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and
386 mortality: a prospective cohort in UK Biobank. *Cardiovasc Res*. 2023;119:1718-1727. doi:
387 10.1093/cvr/cvac195
- 388 4. Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. *Nat Med*.
389 2023;29:2347-2357. doi: 10.1038/s41591-023-02521-2
- 390 5. Raman B, Bluemke DA, Luscher TF, Neubauer S. Long COVID: post-acute sequelae of
391 COVID-19 with a cardiovascular focus. *Eur Heart J*. 2022;43:1157-1172. doi:
392 10.1093/eurheartj/ehac031
- 393 6. Venkatesan P. NICE guideline on long COVID. *Lancet Respir Med*. 2021;9:129. doi:
394 10.1016/S2213-2600(21)00031-X
- 395 7. Fernandez-de-Las-Penas C. Long COVID: current definition. *Infection*. 2022;50:285-286. doi:
396 10.1007/s15010-021-01696-5
- 397 8. Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research I.
398 Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort
399 study. *Lancet*. 2022;400:452-461. doi: 10.1016/S0140-6736(22)01214-4
- 400 9. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and
401 recommendations. *Nat Rev Microbiol*. 2023;21:133-146. doi: 10.1038/s41579-022-00846-2
- 402 10. Healey Q, Sheikh A, Daines L, Vasileiou E. Symptoms and signs of long COVID: A rapid review
403 and meta-analysis. *J Glob Health*. 2022;12:05014. doi: 10.7189/jogh.12.05014
- 404 11. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, Li X, Xu P, Zhang L, Zhao L, et al. SARS-CoV-2 infection
405 of the liver directly contributes to hepatic impairment in patients with COVID-19. *J Hepatol*.
406 2020;73:807-816. doi: 10.1016/j.jhep.2020.05.002
- 407 12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of
408 patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
409 doi: 10.1016/S0140-6736(20)30183-5
- 410 13. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*.
411 2020;17:259-260. doi: 10.1038/s41569-020-0360-5
- 412 14. Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. *Trends*
413 *Pharmacol Sci*. 2004;25:291-294. doi: 10.1016/j.tips.2004.04.001
- 414 15. Sidik SM. Heart-disease risk soars after COVID - even with a mild case. *Nature*. 2022;602:560.
415 doi: 10.1038/d41586-022-00403-0

- 416 16. Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19
417 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX
418 US collaborative networks. *EClinicalMedicine*. 2022;53:101619. doi:
419 10.1016/j.eclinm.2022.101619
- 420 17. Hong K, Kisiju T, Kim J, Chun BC. Cardio-cerebrovascular complications in COVID-19 patients:
421 A retrospective cohort study. *Front Med (Lausanne)*. 2022;9:1045274. doi:
422 10.3389/fmed.2022.1045274
- 423 18. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat Med*.
424 2022;28:583-590. doi: 10.1038/s41591-022-01689-3
- 425 19. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
426 *Nat Med*. 2022;28:2398-2405. doi: 10.1038/s41591-022-02051-3
- 427 20. Lip GYH, Genaidy A, Tran G, Marroquin P, Estes C. Incident atrial fibrillation and its risk
428 prediction in patients developing COVID-19: A machine learning based algorithm approach.
429 *Eur J Intern Med*. 2021;91:53-58. doi: 10.1016/j.ejim.2021.04.023
- 430 21. Salah HM, Fudim M, O'Neil ST, Manna A, Chute CG, Caughey MC. Post-recovery COVID-19 and
431 incident heart failure in the National COVID Cohort Collaborative (N3C) study. *Nat Commun*.
432 2022;13:4117. doi: 10.1038/s41467-022-31834-y
- 433 22. Lam ICH, Wong CKH, Zhang R, Chui CSL, Lai FTT, Li X, Chan EWY, Luo H, Zhang Q, Man KKC, et
434 al. Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database
435 cohort study in Hong Kong and the UK. *EClinicalMedicine*. 2023;60:102000. doi:
436 10.1016/j.eclinm.2023.102000
- 437 23. Ortega-Paz L, Arevalos V, Fernandez-Rodriguez D, Jimenez-Diaz V, Baneras J, Campo G,
438 Rodriguez-Santamarta M, Diaz JF, Scardino C, Gomez-Alvarez Z, et al. One-year cardiovascular
439 outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry. *PLoS One*.
440 2022;17:e0279333. doi: 10.1371/journal.pone.0279333
- 441 24. Tuvali O, Tshori S, Derazne E, Hannuna RR, Afek A, Haberman D, Sella G, George J. The
442 Incidence of Myocarditis and Pericarditis in Post COVID-19 Unvaccinated Patients-A Large
443 Population-Based Study. *J Clin Med*. 2022;11. doi: 10.3390/jcm11082219
- 444 25. Mabila S, Patel D, Fan M, Stahlman S, Seliga N, Nowak G, Wells N. Post -acute sequelae of
445 COVID-19 and cardiac outcomes in U. S. military members. *Int J Cardiol Cardiovasc Risk Prev*.
446 2023;17:200183. doi: 10.1016/j.ijcrp.2023.200183
- 447 26. Raisi-Estabragh Z, Cooper J, Salih A, Raman B, Lee AM, Neubauer S, Harvey NC, Petersen SE.
448 Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank. *Heart*.
449 2022;109:119-126. doi: 10.1136/heartjnl-2022-321492
- 450 27. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19.
451 *Nature*. 2021;594:259-264. doi: 10.1038/s41586-021-03553-9
- 452 28. Katsoularis I, Fonseca-Rodriguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute
453 myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled
454 case series and matched cohort study. *Lancet*. 2021;398:599-607. doi:
455 10.1016/S0140-6736(21)00896-5
- 456 29. Cohen K, Ren S, Heath K, Dasmariñas MC, Jubilo KG, Guo Y, Lipsitch M, Daugherty SE. Risk of
457 persistent and new clinical sequelae among adults aged 65 years and older during the
458 post-acute phase of SARS-CoV-2 infection: retrospective cohort study. *BMJ*.
459 2022;376:e068414. doi: 10.1136/bmj-2021-068414

- 460 30. Zhang HG, Dagliati A, Shakeri Hossein Abad Z, Xiong X, Bonzel CL, Xia Z, Tan BWQ, Avillach P,
461 Brat GA, Hong C, et al. International electronic health record-derived post-acute sequelae
462 profiles of COVID-19 patients. *NPJ Digit Med*. 2022;5:81. doi: 10.1038/s41746-022-00623-8
- 463 31. Tsampasian V, Elghazaly H, Chattopadhyay R, Debski M, Naing TKP, Garg P, Clark A, Ntatsaki E,
464 Vassiliou VS. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and
465 Meta-analysis. *JAMA Intern Med*. 2023;183:566-580. doi: 10.1001/jamainternmed.2023.0750
- 466 32. Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang Y, Zhao Q, et al. Characteristics and
467 clinical significance of myocardial injury in patients with severe coronavirus disease 2019. *Eur*
468 *Heart J*. 2020;41:2070-2079. doi: 10.1093/eurheartj/ehaa408
- 469 33. Ma S, Sun S, Li J, Fan Y, Qu J, Sun L, Wang S, Zhang Y, Yang S, Liu Z, et al. Single-cell
470 transcriptomic atlas of primate cardiopulmonary aging. *Cell Res*. 2021;31:415-432. doi:
471 10.1038/s41422-020-00412-6
- 472 34. Tucker NR, Chaffin M, Bedi KC, Jr., Papangeli I, Akkad AD, Arduini A, Hayat S, Eraslan G, Muus
473 C, Bhattacharyya RP, et al. Myocyte-Specific Upregulation of ACE2 in Cardiovascular Disease:
474 Implications for SARS-CoV-2-Mediated Myocarditis. *Circulation*. 2020;142:708-710. doi:
475 10.1161/CIRCULATIONAHA.120.047911
- 476 35. Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, 3rd, Kwon DH, Singh T,
477 Tilton JC, Tsai EJ, et al. COVID-19 and Cardiovascular Disease: From Bench to Bedside. *Circ Res*.
478 2021;128:1214-1236. doi: 10.1161/CIRCRESAHA.121.317997
- 479 36. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX, Oishi K,
480 Panis M, Sachs D, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of
481 COVID-19. *Cell*. 2020;181:1036-1045 e1039. doi: 10.1016/j.cell.2020.04.026
- 482 37. Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele
483 CE, Neeland IJ, Sanders P, et al. Obesity and Cardiovascular Disease: A Scientific Statement
484 From the American Heart Association. *Circulation*. 2021;143:e984-e1010. doi:
485 10.1161/CIR.0000000000000973
- 486 38. Duncan MS, Greevy RA, Tindle HA, Vasani RS, Lipworth L, Aldrich MC, Lloyd-Jones DM,
487 Freiberg MS. Inclusion of Smoking Data in Cardiovascular Disease Risk Estimation. *JAMA*
488 *Cardiol*. 2022;7:195-203. doi: 10.1001/jamacardio.2021.4990
- 489 39. Duncan MS, Freiberg MS, Greevy RA, Jr., Kundu S, Vasani RS, Tindle HA. Association of
490 Smoking Cessation With Subsequent Risk of Cardiovascular Disease. *JAMA*. 2019;322:642-650.
491 doi: 10.1001/jama.2019.10298
- 492 40. Leigh A, McEvoy JW, Garg P, Carr JJ, Sandfort V, Oelsner EC, Budoff M, Herrington D, Yeboah J.
493 Coronary Artery Calcium Scores and Atherosclerotic Cardiovascular Disease Risk Stratification
494 in Smokers. *JACC Cardiovasc Imaging*. 2019;12:852-861. doi: 10.1016/j.jcmg.2017.12.017
- 495 41. Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH,
496 Sperling LS, American Heart Association Diabetes Committee of the Council on L, et al.
497 Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes:
498 A Scientific Statement From the American Heart Association. *Circulation*.
499 2022;145:e722-e759. doi: 10.1161/CIR.0000000000001040
- 500 42. Doi T, Langsted A, Nordestgaard BG. Elevated Remnant Cholesterol Reclassifies Risk of
501 Ischemic Heart Disease and Myocardial Infarction. *J Am Coll Cardiol*. 2022;79:2383-2397. doi:
502 10.1016/j.jacc.2022.03.384
- 503 43. Trinder M, Francis GA, Brunham LR. Association of Monogenic vs Polygenic

- 504 Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. *JAMA Cardiol.*
505 2020;5:390-399. doi: 10.1001/jamacardio.2019.5954
- 506 44. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti
507 K, Harnden A, Coupland CAC, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias
508 associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med.* 2022;28:410-422.
509 doi: 10.1038/s41591-021-01630-0
- 510 45. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, Watkinson P, Khunti
511 K, Harnden A, Coupland CAC, et al. Risk of Myocarditis After Sequential Doses of COVID-19
512 Vaccine and SARS-CoV-2 Infection by Age and Sex. *Circulation.* 2022;146:743-754. doi:
513 10.1161/CIRCULATIONAHA.122.059970
- 514 46. Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO,
515 Naleway A, Nelson JC, et al. Surveillance for Adverse Events After COVID-19 mRNA
516 Vaccination. *JAMA.* 2021;326:1390-1399. doi: 10.1001/jama.2021.15072
- 517 47. Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein LH, Saliba W.
518 Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in
519 High-Risk Patients. *Clin Infect Dis.* 2023;76:e342-e349. doi: 10.1093/cid/ciac443
- 520 48. Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C,
521 Fennema H, Spiessens B, et al. Safety and Efficacy of Single-Dose Ad26.COVS.2 Vaccine
522 against Covid-19. *N Engl J Med.* 2021;384:2187-2201. doi: 10.1056/NEJMoa2101544
- 523 49. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G,
524 Pan K, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2
525 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide
526 vaccination campaign in Israel: an observational study using national surveillance data.
527 *Lancet.* 2021;397:1819-1829. doi: 10.1016/S0140-6736(21)00947-8

528

529 **Figure legends**

530

531 **Figure 1. Flow diagram outlining the search strategy and study identification for**
532 **meta-analysis.**

533

534 **Figure 2. A meta-analysis of the combined multivariate relative risk of 19**
535 **outcomes.**

536


537 **Figure 3. A meta-analysis of the combined univariable the combined OR of 4**


538 **outcomes.**

Table. 2 Quality assessment of the included studies in the meta-analysis.

Source	Selection	Comparability	Outcome	Total Score
Benjamin Bowe 2022¹⁹	+++	++	+++	8
Benjamin Bowe 2023⁴	++++	++	+++	9
Eric Yuk Fai Wan 2023³	+++	++	++	7
Gregory Y.H. Lip 2021²⁰	++++	++	++	8
Hannah R Whittaker 2021²	++++	++	++	8
Harrison G. Zhang 2022³⁰	+++	++	+	6
Husam M. Salah 2022²¹	+++	++	++	7
Ioannis Katsoularis 2021²⁸	+++	++	+	6
Ivan Chun Hang Lam 2023²²	++++	++	++	8
Ken Cohen 2021²⁹	+++	++	+	6
Kwan Hong 2022¹⁷	++++	++	+	7
Luis Ortega-Pazl 2022²³	++++	++	++	8
Ortal Tuvali 2022²⁴	++++	++	++	8
Sithembile Mabila 2022²⁵	+++	++	++	7
Weijie Wang 2022¹⁶	+++	++	++	7
Yan Xie 2022¹⁸	+++	++	++	7
Zahra Raisi-Estabragh 2022²⁶	++++	++	++	8
Ziyad Al-Aly 2021²⁷	++++	++	++	8

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only





Study ID	OR (95% CI)	% Weight
----------	-------------	----------

Heart Failure

Sithembile Mabila 2022	2.45 (1.95, 3.10)	13.72
Hannah R Whittaker 2021	1.01 (0.88, 1.15)	13.93
Subtotal (I-squared = 97.6%, p = 0.000)	1.56 (0.66, 3.73)	27.65

Myocarditis

Ortal Tuvali 2022	1.00 (0.47, 2.13)	11.32
Sithembile Mabila 2022	7.00 (4.81, 10.20)	13.24
Subtotal (I-squared = 95.1%, p = 0.000)	2.72 (0.40, 18.32)	24.56

Myocardial infarction

Sithembile Mabila 2022	1.23 (0.48, 3.18)	10.20
Ioannis Katsoularis 2021	4.06 (2.27, 7.25)	12.29
Subtotal (I-squared = 77.5%, p = 0.035)	2.37 (0.74, 7.61)	22.49

Pericarditis

Ortal Tuvali 2022	0.63 (0.33, 1.22)	11.89
Sithembile Mabila 2022	3.28 (2.35, 4.57)	13.41
Subtotal (I-squared = 94.9%, p = 0.000)	1.47 (0.29, 7.42)	25.30

Overall (I-squared = 95.5%, p = 0.000)	1.97 (1.11, 3.52)	100.00
--	-------------------	--------

NOTE: Weights are from random effects analysis

.0546

1

18.3